BRAF and melanoma: A long-term benefit of a 12-month adjuvant treatment with a combination of BRAF and MEK inhibitors (dabrafenib and trametinib, respectively) has been observed in patients with resected stage III BRAF V600 mutant melanoma [21,22]; in a recent update, median relapse-free survival was not reached in treated patients after a median follow-up of 60 months [23].